Full-Time

Medical Monitor

Canada Board-Certified Psychiatrist

PSI CRO

PSI CRO

1,001-5,000 employees

Global CRO delivering on-time patient enrollment

Compensation Overview

CA$170k - CA$185k/yr

Remote in Canada

Remote

Remote within Canada; must reside in Canada.

Category
Medical, Clinical & Veterinary (1)

Get referred to PSI CRO

See people who can refer or advise you

Requirements
  • Medical Doctor degree required
  • Canada Board Certification in psychiatry required
  • Experience as a practicing psychiatrist (minimum of 10 years)
  • Proficiency with MS Office applications
  • Communication, presentation and analytical skills
  • Problem-solving, team and detail-oriented
Responsibilities
  • Acts as the primary point of contact for all parties on all trial-specific medical and safety-related questions
  • Provides input for responses to regulatory authorities and Institutional Review Boards (IRBs)/Independent Ethics Committees (IECs) on trial-specific medical and safety-related questions
  • Monitors trial participant safety
  • Participates in trial participant recruitment boost and retention activities
  • Presents on medical matters at kick-off and investigator meetings
  • Trains trial team in the therapeutic area and medical aspects of the protocol
  • Develops and reviews trial-specific documents within the scope of medical monitoring
  • Manages ongoing trial risks related to medical monitoring
  • Performs ongoing medical review of the operational clinical trial database; provides support to Medical Reviewer(s) assigned to the trial
  • Reviews protocol deviations
  • Reviews RAE reports, writes and/or reviews SAE narratives, supports Pharmacovigilance team with outstanding safety queries, interacts with sponsor on site safety issues
  • Reviews IND/SUSAR Safety Reports, updates/amendments to essential trial records, and annual IND reports with sponsor data (per sponsor request)
  • Participates in management of trial-related committees (e.g., independent data monitoring committee (IDMC)/adjudication committees) as described in the corresponding trial-specific charter(s))
  • Supports Pharmacovigilance, Medical Data Review and Data Management with reconciliation of safety and operational clinical trial databases
  • Reviews clinical study reports (CSRs), including safety narratives and tables, figures, and listings (TFLs)
  • Provides medical expertise on an as-needed basis in trials where medical monitoring is not a contract deliverable
  • Prepares for and participates in trial audits, follows up on audit findings
  • Participates in feasibility assessment of potential and ongoing trials in the country/region
  • Participates in bid defense meetings and other interactions with clients
  • Acts as a medical expert and provides therapeutic expertise to other PSI departments
Desired Qualifications
  • Clinical Research experience preferred

PSI CRO is a global contract research organization that handles clinical trials for multiple therapeutic areas, with a focus on enrolling patients on schedule and delivering studies on time. Its services span feasibility assessments, trial planning, site selection, patient recruitment, and multi-continent trial execution across 50+ countries, backed by medical doctor resources dedicated to accurate timeline predictions. Unlike many CROs, PSI emphasizes predictable enrollment and on-time project delivery, aiming for high client satisfaction and repeat business through a pragmatic, no-nonsense approach. The company’s goal is to be regarded as the best CRO in the world by both clients and employees, achieved through reliable timelines, strong execution, and low staff turnover.

Company Size

1,001-5,000

Company Stage

N/A

Total Funding

N/A

Headquarters

Switzerland

Founded

1995

Get referred to PSI CRO

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • China expansion deepens local operational and regulatory support for sponsors.
  • Beijing access can shorten decision cycles and improve on-time trial delivery.
  • SYNETIC reduces non-enrolling site exposure, improving feasibility and study economics.

What critics are saying

  • China regulatory tightening can delay studies and weaken sponsor confidence.
  • Competitors with deeper Beijing footprints can win China-linked trials from PSI.
  • AI site-selection tools commoditize PSI's speed advantage and pressure pricing.

What makes PSI CRO unique

  • PSI CRO opened a second China office in Beijing on April 28, 2026.
  • The Beijing office sits near regulators and investigator sites in Chaoyang District.
  • SYNETIC cuts trial site identification from six weeks to minutes with explainable outputs.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Paid Vacation

Flexible Work Hours

Hybrid Work Options

Remote Work Options

Wellness Program

Mental Health Support

Conference Attendance Budget

Professional Development Budget

Company News

PR Newswire
Mar 19th, 2026
PSI cuts clinical trial site selection from 6 weeks to minutes with AI agent on Arango platform

PSI CRO, a global clinical research organisation, has reduced clinical trial site identification from up to six weeks to minutes using SYNETIC, an AI knowledge engine powered by the Arango Contextual Data Platform. The system helps identify higher-performing trial sites and minimise costly non-enrolling institutions, which account for 30-40% of trial sites. Clinical trials can cost over $160 per minute operationally, and activating a trial site costs $30,000 or more. With 15% of sites never enrolling a single patient, failed recruitment can cost millions per study. SYNETIC unifies fragmented clinical research data into a single contextual layer, preserving relationships across investigators, institutions, protocols and historical outcomes. The platform provides explainable AI recommendations, including rationale, supporting evidence and confidence levels, enabling data-driven site selection in minutes rather than weeks.

PharmiWeb.com
Jan 7th, 2026
PSI CRO Strengthens Canadian Presence with New Toronto Office and Leadership Role

PSI CRO strengthens Canadian presence with new Toronto office and leadership role. PSI CRO has broadened its footprint in Canada by opening a new office in the Toronto area and naming an experienced industry leader to guide its operations there. The office, located in Mississauga, Ontario, builds on the company's established Canadian presence and commitment to clinical research excellence. PSI CRO has been active in Canada for over a decade, supporting complex clinical trials with a focus on dependable delivery and strong relationships with research sites. As part of this expansion, David Allen, MBA, has been appointed as Country Manager for Canada. Allen brings more than 30 years of experience in clinical research from both sponsor and CRO environments. In his new role, he will lead efforts to enhance the company's operational capabilities in the local market and ensure alignment with PSI's global standards for on-time trial execution. PSI's continued growth in North America reflects broader trends of increasing trial activity in the region, particularly for pivotal phase II and phase III studies where precision and efficiency are critical. The expanded Toronto operations aim to further support sponsors with rigorous trial planning and execution.

PSI CRO
Mar 13th, 2025
PSI CRO Appoints Sayaka Kaji as Country Manager Japan

TOKYO, 14 March 2025 - PSI CRO AG, a global Swiss-based clinical research organization (CRO), is pleased to announce the appointment of Sayaka Kaji as Country Manager for Japan.

PSI CRO
Sep 6th, 2023
PSI FAQs: How does PSI reduce CRA staff turnover on your project?

Psi CRO Ag launched a CRA Academy to provide to help its team members develop therapeutic expertise as well as soft skills to manage key relationships with sites.

PSI CRO
Jun 13th, 2022
Psi CRO Ag receives award CRO Leadership Awards

This is also the fourth year in a row in which PSI CRO received CRO Leadership Awards in all five categories, also including Expertise and Capabilities, across two respondent groups.